Focus on the Organ and Tissue Transplantation and Alternatives
2008-10-30 19:43:04 -
www.reportlinker.com - Reportlinker.com announces that a new market research report related to the Pharmaceutical industry industry is available in its catalogue.
Organ and Tissue Transplantation and Alternatives
www.reportlinker.com/p096592/Organ-and-Tissue- Transplantation-and-Alternatives.html
(Due to its length, this URL may need to be copied/pasted into your Internet browser's address field. Remove the extra space if one exists.)
STUDY GOALS AND OBJECTIVES
The objective of this study is to provide an in-depth analysis and forecast of the solid organ and tissue transplantation markets. The focus is on products and procedures used or under development for organ and tissue transplantations, including techniques, therapies, drugs, and diagnostics.
REASONS FOR DOING THE STUDY
Organ transplantation is a dynamic field, with continued progress being made in artificial organs and transplantation methods that reduce rejection and infection. There is increased pressure to perfect transplantation methods because the need for organ donors far outstrips the availability of organs and tissues and governmental regulations have become more stringent. In theory, transplantation is the last therapeutic option available to people in the final stage of an organ or tissue failure. In reality, the supply of organs or tissues is so limited that for the vast majority of people, transplantation is not an option.
Despite the lack of organs, the transplantation business continues to innovate through better harvesting and procurement techniques, vastly improved immunosuppression regimes, and advanced tissue matching, which have helped build the organ and tissue transplantation business to a maturing stage. This report will focus on procurement, transplantation by organ, immunosuppressives and other pharmaceuticals, post-transplantation concerns, and alternatives to transplantation.
Although the organ transplantation business faces tough challenges, it also offers exciting fields of research and tremendous opportunities to meet growing market demand and to cut costs. This report is a valuable tool for anyone assessing the organ and tissue transplantation market and attempting to devise a strategy to successfully address it.
INTENDED AUDIENCE
This study provides a thorough background on the structure of the organ and tissue transplantation market and the chief issues it faces. It offers the information needed to understand the current market and to address the emerging one. This is an invaluable tool for business planners, acquisitions specialists, licensing strategists, product managers, market research analysts, investing consultants, and others interested in the tissue and transplantation market, its products, its participants, and its future.
CHAPTER 1: INTRODUCTION
STUDY GOAL AND OBJECTIVES
REASONS FOR DOING THE STUDY
INTENDED AUDIENCE
SCOPE OF REPORT
METHODOLOGY
INFORMATION SOURCES
AUTHOR'S CREDENTIALS
RELATED BCC PUBLICATIONS
BCC ONLINE SERVICES
DISCLAIMER
CHAPTER 2: SUMMARY
SUMMARY
SUMMARY TABLE U.S. MARKET FOR SOLID ORGAN AND TISSUE TRANSPLANTATION, THROUGH 2013 ($ MILLIONS)
SUMMARY FIGURE U.S. MARKET FOR SOLID ORGAN AND TISSUE TRANSPLANTATION, 2007-2013 ($ MILLIONS)
CHAPTER 3: INDUSTRY OVERVIEW
INDUSTRY OVERVIEW
HISTORY OF TRANSPLANTATION
TISSUE TYPING
IMMUNOSUPPRESSION
Newer Immunosuppressive Drugs
PRESERVATION
GOVERNMENT REIMBURSEMENT
THE TRANSPLANTATION PROCESS
PREPARATION
SURGERY
RECUPERATION
MAINTENANCE
IMPORTANCE OF THE INDUSTRY
ORGANS
TABLE 1 U.S. ORGAN TRANSPLANTS: AVERAGE FIRST YEAR COST, NUMBER OF PROCEDURES AND VALUE BY TYPE OF ORGAN TRANSPLANT, THROUGH 2013 ($ MILLIONS)
KIDNEY
TABLE 2 LEADING U.S. KIDNEY TRANSPLANT PROGRAMS BY TOTAL NUMBER OF PROCEDURES PERFORMED IN 2007
LIVER
TABLE 3 TOP FIVE U.S. LIVER TRANSPLANT PROGRAMS BY TOTAL PROCEDURES PERFORMED IN 2007
HEART
TABLE 4 TOP FIVE U.S. HEART TRANSPLANT PROGRAMS BY TOTAL PROCEDURES PERFORMED IN 2007
LUNG
TABLE 5 TOP FIVE U.S. LUNG TRANSPLANT PROGRAMS BY TOTAL PROCEDURES PERFORMED IN 2007
INTESTINE
TABLE 6 TOP FIVE U.S. INTESTINE/SMALL BOWEL TRANSPLANT PROGRAMS BY TOTAL PROCEDURES PERFORMED IN 2007
PANCREAS
TABLE 7 TOP FIVE U.S. PANCREAS TRANSPLANT PROGRAMS BY TOTAL PROCEDURES PERFORMED IN 2007
TISSUES
DRIVERS IN THE MARKET
TABLE 8 TISSUE GRAFTING IN THE U.S. BY TISSUE TYPE, THROUGH 2013 (MILLION PROCEDURES)
FIGURE 1 U.S. MARKET FOR TISSUE GRAFTING PROCEDURES BY TYPE, 2007-2013 (MILLION PROCEDURES)
CORNEA
BLOOD STEM CELLS
BONE ALLOGRAFTS
HEART VALVES
VASCULAR TISSUE
SKIN AND COLLAGEN
Applications
WAITING LISTS OUTPACE DONATIONS
TABLE 9 PATIENTS ON U.S. WAITING LISTS AT THE END OF THE YEAR BY TYPE OF ORGAN TRANSPLANT, 2003-2006
TRENDS IN U.S. LIVING AND CADAVERIC DONATIONS
TABLE 10 TRENDS IN U.S. LIVING AND CADAVERIC DONATIONS, THROUGH 2013
TRENDS IN TRANSPLANTATION OF ALL ORGANS
TABLE 11 U.S. ORGAN TRANSPLANTS, THROUGH 2006 (NUMBER OF PROCEDURES)
INTERNATIONAL TRENDS
TABLE 12 NUMBERS OF DONATED CADAVERS BY REGION, 2003-2006
LIMITED SUPPLY CURTAILS TRANSPLANTATIONS
Living Donor Programs
KEY FACTORS IN INDUSTRY GROWTH
Reducing Demand
Patient Survival Rates
TABLE 13 ONE-YEAR AND FIVE-YEAR PATIENT SURVIVAL RATES, BY ORGAN FOR TRANSPLANTS PERFORMED, 1997-2004 (%)
TABLE 14 ONE-YEAR AND FIVE-YEAR GRAFT SURVIVAL RATES, BY ORGAN FOR TRANSPLANTS PERFORMED, 1997-2004 (%)
TABLE 14 (CONTINUED)
TABLE 15 NUMBER OF PEOPLE IN THE U.S. LIVING WITH A FUNCTIONING TRANSPLANT BY TYPE, 2000-2005*
Organ Substitutes
Organs from Animals: Xenotransplantation
Organ Primordia
Nuclear Transfer to Eliminate the Rejection Gene
Porcine Endogenous Retrovirus
ARTIFICIAL ORGANS
CELLULAR TRANSPLANTS
KEY FACTORS INHIBITING GROWTH
LACK OF DONORS
ALTERNATIVE THERAPIES
CULTURAL STIGMAS
CHAPTER 4: GOVERNMENT REGULATIONS
GOVERNMENT REGULATIONS
THE MEDICARE DRUG DISCOUNT CARD PROGRAM, MEDICARE DRUG BENEFITS, AND TRANSPLANT PATIENTS
TABLE 16 IMMUNOSUPPRESSIVE DRUGS CURRENTLY COVERED BY MEDICARE*
TABLE 17 MEDICARE IMMUNOSUPPRESIVE DRUG COVERAGE OVERVIEW
CHAPTER 5: TRANSPLANTATION PRODUCTS AND PHARMACEUTICALS
HLA TISSUE TYPING
THE WORLD MARKET FOR HLA TYPING
TABLE 18 WORLD MARKET FOR HLA TYPING, THROUGH 2013 ($ MILLIONS)
THE U.S. MARKET FOR HLA TYPING
TABLE 19 U.S. MARKET FOR HLA TYPING, THROUGH 2013 ($ MILLIONS)
ORGAN PRESERVATION PRODUCTS
TABLE 20 PRESERVATION TIME FOR TRANSPLANTED ORGANS (HOURS)
Custodiol
Warm Organ Perfusion
IMMUNOSUPPRESSION
TABLE 21 IMMUNOSUPPRESSIVE DRUGS APPROVED IN THE U.S. BY CLASS
Antibodies
TABLE 22 ANTIBODY PRODUCTS FOR TREATMENT OF ORGAN TRANSPLANT REJECTION
TABLE 23 COMMONLY USED INTRAVENOUS ANTIBODY IMMUNOSUPPRESIVE DRUGS
TABLE 23 (CONTINUED)
OKT-3
Zenapax
Simulect
Campath/MabCampath
Polyclonal Antibody Products
Atgam
Thymoglobulin
The Market for Antibody Products to Treat Organ Transplant Rejection
TABLE 24 GLOBAL MARKET FOR ANTIBODY PRODUCTS TO TREAT ORGAN TRANSPLANT REJECTION, THROUGH 2013 ($ MILLIONS)
FIGURE 2 GLOBAL MARKET FOR ANTIBODY PRODUCTS USED IN ORGAN TRANSPLANTATION, 2007-2013 ($ MILLIONS)
Antiproliferative Agents
Azathioprine
CellCept
Myfortic
TABLE 25 GLOBAL MARKET FOR ANTIPROLIFERATIVE AGENTS TO TREAT ORGAN TRANSPLANT REJECTION: WORLDWIDE SALES, THROUGH 2013 ($ MILLIONS)
FIGURE 3 GLOBAL MARKET FOR ANTIPROLIFERATIVE AGENTS, 2007-2013 ($ MILLIONS)
Calcineurin Inhibitors
Tacrolimus
Cyclosporine
Generic Cyclosporine
TABLE 26 GLOBAL MARKET FOR CALCINEURIN INHIBITORS TO TREAT ORGAN TRANSPLANT REJECTION: WORLDWIDE SALES, THROUGH 2013 ($ MILLIONS)
FIGURE 4 GLOBAL MARKET FOR CALCINEURIN INHIBITORS, 2007-2013 ($ MILLIONS)
Source: BCC Research
M-TOR Inhibitors
Certican
Rapamune
TABLE 27 GLOBAL MARKET FOR M-TOR INHIBITORS TO TREAT ORGAN TRANSPLANT REJECTION: WORLDWIDE SALES, THROUGH 2013 ($ MILLIONS)
Concern About Generics
TABLE 28 U.S. SALES OF IMMUNOSUPPRESSIVES BY DRUG CATEGORY, THROUGH 2013 ($ MILLIONS)
FIGURE 5 U.S. SALES OF IMMUNOSUPPRESSIVES, BY CATEGORY, THROUGH 2013 ($ MILLIONS)
IMMUNOSUPPRESSIVE AGENTS IN DEVELOPMENT
TABLE 29 SELECTED IMMUNOSUPPRESSIVE AGENTS IN PHASE 1 OR LATER DEVELOPMENT
TABLE 29 (CONTINUED)
TOLERANCE
Antisense Therapy
Costimulation
Chimerism
USUAL ANTI-REJECTION DRUG PROTOCOLS
TABLE 30 COMMON IMMUNOSUPPRESSIVE REGIMENS
INDUCTION THERAPY
TABLE 31 IMMUNOSUPPRESSANT USE FOR INDUCTION, BY ORGAN IN 2006 (%)
MAINTENANCE THERAPY
TABLE 32 IMMUNOSUPPRESSANT USE FOR MAINTENANCE AT DISCHARGE BY ORGAN IN THE U.S., 2006 (%)
TABLE 33 IMMUNOSUPPRESSANT USE FOR MAINTENANCE AT 1-YEAR POST-TRANSPLANT BY ORGAN IN U.S., 2006 (%)
REJECTION THERAPY
Risks Associated with Immunosuppressive Therapy
Annual Cost of Immunosuppressant Drugs
The World Market for Immunosuppressant Drug Therapy
TABLE 34 WORLDWIDE MARKET FOR IMMUNOSUPPRESSION IN SOLID ORGAN TRANSPLANT RECIPIENTS, THROUGH 2013
TABLE 35 GLOBAL SALES OF IMMUNOSUPPRESSIVES BY DRUG CATEGORY, THROUGH 2013 ($ MILLIONS)
FIGURE 6 WORLDWIDE SALES OF IMMUNOSUPPRESSANTS BY CATEGORY, 2007-2013 ($ MILLIONS)
TABLE 36 WORLDWIDE SALES OF BRAND NAME IMMUNOSUPPRESSANT DRUGS BY COMPANY, 2006 AND 2007 ($ MILLIONS)
PRODUCTS
ADDRESSING INFECTION
GRAFT-VERSUS-HOST DISEASE
POST-TRANSPLANT INFECTIONS
ViroPharma Incorporated
Cardiovascular Disease
TABLE 37 COMMON POST-TRANSPLANT INFECTIONS
TABLE 38 TIMELINE FOR POST-TRANSPLANT INFECTION
TABLE 39 COMMON POST-TRANSPLANT DRUGS
TABLE 40 WORLD MARKET FOR ANTI-INFECTIVES USED FOR TRANSPLANT PATIENTS, THROUGH 2013 ($ MILLIONS)
POST-TRANSPLANT MONITORING
TABLE 41 U.S. MARKET FOR POST-TRANSPLANT MONITORING, THROUGH 2013 ($ MILLIONS)
Cylex
CHAPTER 6: PROCUREMENT AND HARVESTING
INCREASING SUPPLY
SUPPLY MANAGEMENT
REDUCING WASTE AND REJECTION
INCREASING THE HARVEST
TABLE 42 RECOVERED ORGANS NOT USED BY TYPE, 2003-2006
TABLE 43 CONSENTED ORGANS NOT RECOVERED BY TYPE, 2003-2006
BETTER HARVESTING
DEFINITION OF BRAIN DEATH
PROTECTING HARVESTED ORGANS
HORMONAL RESUSCITATION
NON-HEART-BEATING DONORS
LESS WASTE
PRESERVATION
ORGAN PRESERVATION METHODS
Rinse and Preservation Solutions
TABLE 44 MAJOR ORGAN PRESERVATION SOLUTIONS
Celsior
Collins Solution
Custodiol
Hypothermosol
ViaSpan
Market for Preservation Solutions
TABLE 45 NORTH AMERICAN AND WORLD MARKETS FOR ORGAN PRESERVATION SOLUTIONS (NOT INCLUDING THE PAPWORK COCKTAIL), THROUGH 2013 ($ MILLIONS)
Organ Preservation Products in Development
Human BioSystems
Trophic Solutions
Machine Perfusion
Waters Medical Systems
TransMedics, Inc
FIGHTING REJECTION
TABLE 46 U.S. ORGAN RECIPIENTS WHO PREVIOUSLY HAD A TRANSPLANT: ALL ORGANS, 2003-2006
CHAPTER 7: SOLID ORGAN TRANSPLANTATION
TRANSPLANT CENTERS
TABLE 47 LEADING U.S. TRANSPLANT PROGRAMS BY TOTAL NUMBER OF PROCEDURES PERFORMED IN 2007
TESTING
Blood Typing
Tissue Typing
Panel Reactive Antibodies (PRA)
TABLE 48 TISSUE TYPING TECHNOLOGIES
Advances
TABLE 49 SELECTED COMPETITORS IN THE HLA TYPING MARKET
Plasmapheresis: Transplantation without Matching
Antigens
KIDNEY
MARKET FOR KIDNEY TRANSPLANTS
TABLE 50 U.S. MARKET FOR KIDNEY-ONLY TRANSPLANTATION, THROUGH 2013
MARKET FOR IMMUNOSUPPRESSIVES FOR KIDNEY TRANSPLANTATION
TABLE 51 ESTIMATED U.S. MARKET FOR IMMUNOSUPPRESSIVES FOR KIDNEY TRANSPLANT PATIENTS, THROUGH 2013 ($ MILLION)
IMMUNOSUPPRESSION
Drugs Used for Induction
TABLE 52 U.S. IMMUNOSUPPRESSION DRUG USE FOR INDUCTION IN KIDNEY TRANSPLANTATION, 2003-2006 (%)
Drugs Used for Maintenance Prior to Discharge
TABLE 53 U.S. IMMUNOSUPPRESSION DRUG USE FOR MAINTENANCE BEFORE DISCHARGE AFTER KIDNEY TRANSPLANTATION, 2003-2006 (%)
Drugs Used for Maintenance between Discharge and Oneyear Post-transplant
TABLE 54 IMMUNOSUPPRESSION DRUG USE IN THE U.S. FOR MAINTENANCE BETWEEN DISCHARGE AND ONE-YEAR POSTTRANSPLANT FOR KIDNEY TRANSPLANTATION, 2002-2005 (%)
ALTERNATIVES
Mechanical
Medical
Animal
Cellular
PANCREAS
MARKET FOR PANCREAS TRANSPLANTATION
TABLE 55 U.S. MARKET FOR PANCREAS TRANSPLANTATION, THROUGH 2013
WAITING LIST
TABLE 56 U.S. PANCREAS WAITING LIST, THROUGH 2013
IMMUNOSUPPRESSION
TABLE 57 ESTIMATED U.S. MARKET FOR IMMUNOSUPPRESSIVES FOR PANCREAS TRANSPLANT PATIENTS, THROUGH 2013
Drugs Used for Induction
TABLE 58 U.S. IMMUNOSUPPRESSION DRUG USE FOR INDUCTION IN PANCREAS TRANSPLANTATION, 2003-2006 (%)
Drugs Used for Maintenance Prior to Discharge
TABLE 59 U.S. IMMUNOSUPPRESSION DRUG USE FOR MAINTENANCE BEFORE DISCHARGE AFTER PANCREAS TRANSPLANTATION, 2003-2006 (%)
Drugs Used for Maintenance between Discharge and Oneyear Post-transplant
TABLE 60 IMMUNOSUPPRESSION DRUG USE IN THE U.S. FOR MAINTENANCE BETWEEN DISCHARGE AND 1-YEAR POSTTRANSPLANT FOR PANCREAS TRANSPLANTATION, 2002-2005 (%)
PREVALANCE OF DIABETES
ALTERNATIVES
HEART
TABLE 61 U.S. HEART TRANSPLANT MARKET, THROUGH 2013 ($ MILLIONS)
SUPPLY
Cultural Backlash
Accepting Brain Death is Crucial
WAITING LISTS
IMMUNOSUPPRESSION
TABLE 62 ESTIMATED U.S. MARKET FOR IMMUNOSUPPRESSIVES FOR HEART TRANSPLANT PATIENTS, THROUGH 2013
Drugs Used for Induction
TABLE 63 U.S. IMMUNOSUPPRESSION DRUG USE FOR INDUCTION IN HEART TRANSPLANTATION, 2003-2006 (%)
Drugs Used for Maintenance Prior to Discharge
TABLE 64 U.S. IMMUNOSUPPRESSION DRUG USE FOR MAINTENANCE PRIOR TO DISCHARGE IN HEART TRANSPLANTATION, 2003-2006 (%)
TABLE 64 (CONTINUED)
Drugs Used for Anti-rejection between Discharge and 1-year Post-transplant
TABLE 65 U.S. IMMUNOSUPPRESSION DRUG USE FOR ANTIREJECTION BETWEEN DISCHARGE AND 1-YEAR POSTTRANSPLANT IN HEART TRANSPLANTATION, 2002-2005
INDICATIONS
TABLE 66 LEADING CAUSES OF HEART FAILURE, 2002-2006 (%)
TISSUE TYPING
PRESERVATION
ALTERNATIVES
LIVER
HISTORY
TRANSPLANT STATISTICS
ORGAN RECOVERY
THE MARKET FOR LIVER TRANSPLANTATION
TABLE 67 U.S. LIVER TRANSPLANT MARKET, FIRST YEAR, THROUGH 2013 ($ MILLIONS)
DONORS
WAITING LISTS
TABLE 68 REGIONAL GROWTH IN LIVER WAITING LISTS, THROUGH 2013
IMMUNOSUPPRESSION
Drugs Used for Induction
TABLE 69 U.S. IMMUNOSUPPRESSION DRUG USE FOR INDUCTION IN LIVER TRANSPLANTATION, 2003-2006 (%)
Drugs Used for Maintenance Prior to Discharge
TABLE 70 U.S. IMMUNOSUPPRESSION DRUG USE FOR MAINTENANCE PRIOR TO DISCHARGE IN LIVER TRANSPLANTATION, 2003-2006 (%)
Drugs Used for Maintenance between Discharge and 1-Year Post-transplant
TABLE 71 U.S. IMMUNOSUPPRESSION DRUG USE FOR MAINTENANCE BETWEEN DISCHARGE AND 1-YEAR POSTTRANSPLANT FOR LIVER TRANSPLANTATION, 2002-2005 (%)
Drugs Used for Anti-rejection between Transplant and 1-Year Post-Transplant
TABLE 72 U.S. IMMUNOSUPPRESSION DRUG USE FOR ANTIREJECTION BETWEEN TRANSPLANT AND 1-YEAR POSTTRANSPLANT FOR LIVER TRANSPLANTATION, 2002-2005 (%)
TABLE 72 (CONTINUED)
The Market for Immunosuppressive Drugs in Liver Transplantation
TABLE 73 ESTIMATED U.S. MARKET FOR IMMUNOSUPPRESSIVES FOR LIVER TRANSPLANT PATIENTS, THROUGH 2013 ($ MILLIONS)
INDICATIONS
Causes of Cirrhosis
TISSUE TYPING
ORGAN REJECTION
TABLE 74 LIVER TRANSPLANT SURVIVAL RATES IN THE U.S. AND EUROPE, 2003 (%)
LUNGS
TRANSPLANTATION STATISTICS
THE MARKET FOR LUNG TRANSPLANTATION
TABLE 75 U.S. LUNG TRANSPLANTATION MARKET, THROUGH 2013 ($ MILLIONS)
WAITING LISTS
INDICATIONS
TABLE 76 LEADING CAUSES OF CHRONIC LUNG FAILURE IN THE U.S., 2002-2006 (%)
DONATION
IMMUNOSUPPRESSION
TABLE 77 ESTIMATED U.S. MARKET FOR IMMUNOSUPPRESSIVES FOR LUNG TRANSPLANT PATIENTS, THROUGH 2013 ($ MILLIONS)
Drugs Used for Induction
TABLE 78 U.S. IMMUNOSUPPRESSION DRUG USE FOR INDUCTION IN LUNG TRANSPLANTATION, 2003-2006 (%)
Drugs Used for Maintenance Prior to Discharge
TABLE 79 U.S. IMMUNOSUPPRESSION DRUG USE FOR MAINTENANCE PRIOR TO DISCHARGE IN LUNG TRANSPLANTATION, 2002-2006 (%)
Drugs Used for Maintenance between Discharge and 1-Year Post-Transplant
TABLE 80 U.S. IMMUNOSUPPRESSION DRUG USE FOR MAINTENANCE BETWEEN DISCHARGE AND 1-YEAR POSTTRANSPLANT IN LUNG TRANSPLANTATION, 2003-2006 (%)
Drugs Used for Anti-rejection between Transplant and 1-Year Post-Transplant
TABLE 81 U.S. IMMUNOSUPPRESSION DRUG USE FOR ANTIREJECTION BETWEEN TRANSPLANT AND 1-YEAR POSTTRANSPLANT IN LUNG TRANSPLANTATION, 2002-2005 (%)
TABLE 81 (CONTINUED)
REJECTION
TABLE 82 U.S. LUNG TRANSPLANT PATIENT AND GRAFT SURVIVAL RATES* (%)
ALTERNATIVES
HEART-LUNG
THE MARKET FOR HEART-LUNG TRANSPLANTATION
TABLE 83 U.S. HEART-LUNG TRANSPLANT MARKET, THROUGH 2013 ($ MILLIONS)
IMMUNOSUPPRESSION
TABLE 84 ESTIMATED U.S. MARKET FOR IMMUNOSUPPRESSIVES FOR HEART-LUNG TRANSPLANT PATIENTS, THROUGH 2013 ($ MILLIONS)
Drugs Used for Induction
TABLE 85 U.S. IMMUNOSUPPRESSION DRUG USE FOR INDUCTION IN HEART-LUNG TRANSPLANTATION, 2003-2006 (%).... 122
Drugs Used for Maintenance Prior to Discharge
TABLE 86 U.S. IMMUNOSUPPRESSION DRUG USE FOR MAINTENANCE PRIOR TO DISCHARGE IN HEART-LUNG TRANSPLANTATION, 2003-2006 (%)
Drugs Used for Maintenance between Discharge and 1-Year Post-Transplant
TABLE 87 U.S. IMMUNOSUPPRESSION DRUG USE FOR MAINTENANCE BETWEEN DISCHARGE AND 1-YEAR POSTTRANSPLANT IN HEART-LUNG TRANSPLANTATION, 2002-2005 (%)
Drugs Used for Anti-rejection between Transplant and 1-Year Post-Transplant
TABLE 88 U.S. IMMUNOSUPPRESSION DRUG USE FOR ANTIREJECTION BETWEEN TRANSPLANT AND 1-YEAR POSTTRANSPLANT IN HEART-LUNG TRANSPLANTATION, 2002-2005 (%)
WAITING LISTS
TABLE 89 U.S. HEART-LUNG WAITING LIST TRENDS, THROUGH 2013
SURVIVAL RATES
TABLE 90 U.S. HEART-LUNG TRANSPLANT PATIENT AND GRAFT SURVIVAL RATES (%)
INTESTINE/SMALL BOWEL
HISTORY
TRANSPLANT TYPES
INDICATIONS
TABLE 91 LEADING INDICATIONS FOR INTESTINE TRANSPLANT: ADULT PATIENTS
TABLE 92 LEADING INDICATIONS FOR INTESTINE TRANSPLANT: PEDIATRIC PATIENTS
U.S. TRANSPLANTATION STATISTICS
TABLE 93 U.S. SMALL BOWEL TRANSPLANTATION TRENDS, THROUGH 2013
THE MARKET FOR INTESTINE TRANSPLANTATION
TABLE 94 U.S. SMALL BOWEL TRANSPLANTATION MARKET, THROUGH 2013 ($ MILLIONS)
COUNTRIES WITH SMALL BOWEL/INTESTINES TRANSPLANT PROGRAMS
TABLE 95 COUNTRIES WITH SMALL BOWEL TRANSPLANT PROGRAMS
IMMUNOSUPPRESSION
TABLE 96 ESTIMATED U.S. MARKET FOR IMMUNOSUPPRESSIVES FOR HEART-LUNG TRANSPLANT PATIENTS, THROUGH 2013 ($ MILLIONS)
Drugs Used for Induction
TABLE 97 U.S. IMMUNOSUPPRESSION DRUG USE FOR INDUCTION IN INTESTINE TRANSPLANTATION, 2003-2006 (%)
Drugs Used for Maintenance Prior to Discharge
TABLE 98 U.S. IMMUNOSUPPRESSION DRUG USE FOR MAINTENANCE PRIOR TO DISCHARGE IN INTESTINE TRANSPLANTATION, 2003-2006 (%)
Drugs Used for Maintenance between Discharge and 1-Year Post-Transplant
TABLE 99 U.S. IMMUNOSUPPRESSION DRUG USE FOR MAINTENANCE BETWEEN DISCHARGE AND 1-YEAR POSTTRANSPLANT IN INTESTINE TRANSPLANTATION, 2002-2005 (%)
Drugs Used for Anti-rejection between Transplant and 1-Year Post-Transplant
TABLE 100 U.S. IMMUNOSUPPRESSION DRUG USE FOR ANTIREJECTION BETWEEN TRANSPLANT AND 1-YEAR POSTTRANSPLANT IN INTESTINE TRANSPLANTATION, 2002-2005 (%)
TABLE 100 (CONTINUED)
INFECTION PROPHYLAXIS
ALTERNATIVES
CHAPTER 8: TISSUE TRANSPLANTATION
OVERVIEW
FEWER DONATIONS DUE TO PUBLIC MISTRUST
Compensation
Cosmetic Tissue Usage
CORNEA
HISTORY
GLOBAL ESTIMATES OF VISUAL IMPAIRMENT
CORNEAL TRANSPLANTS IN THE U.S.
TABLE 101 U.S. CORNEAL TRANSPLANT MARKET, THROUGH 2013
Waiting Lists
Waiting Lists: Other Countries
Tissue Testing
Preservation
Cryopreservation
Immunosuppression
ALTERNATIVES
BLOOD STEM CELLS
HISTORY
First Successful Transplant
Donor Registry Established
INDICATIONS
Cord Blood
Cord Blood Banking
PROCEDURE VOLUMES
TABLE 102 PROJECTED U.S. HEMATOPOIETIC STEM CELL TRANSPLANT PROCEDURES, THROUGH 2013
Autologous Versus Allogeneic
DONORS
TABLE 103 BMDW MEMBER HOME COUNTRIES
Blood Collection in the U.S.
TABLE 104 NUMBER OF BONE MARROW DONORS, BY COUNTRY
WAITING LISTS
REJECTION
IMMUNOSUPPRESSION
Enzo Biochem
MARKET FOR IMMUNOSUPPRESSANTS IN BLOOD STEM CELL TRANSPLANTS
TABLE 105 U.S. MARKET FOR IMMUNOSUPPRESSIVE DRUG THERAPY FOLLOWING HEMATOPOIETIC TRANSPLANTATION, THROUGH 2013 ($ MILLIONS)
CORD BLOOD
Increasing the Number of Cord Blood Cells
BONE GRAFT TRANSPLANTATION
HISTORY
GLOBAL BONE GRAFT MARKET
PROCEDURES
TABLE 106 U.S. BONE GRAFT PROCEDURE VOLUMES BY TYPE OF GRAFT, THROUGH 2013
FIGURE 7 U.S. BONE GRAFT PROCEDURES, 2007-2013 ($ MILLIONS)
Spinal Fusion
Joint Replacement
INDICATIONS
ORTHOPEDIC IMPLANT MARKET
TABLE 107 U.S. AND WORLDWIDE ORTHOPEDIC IMPLANT MARKET GROWTH, THROUGH 2013 ($ MILLIONS)
TABLE 108 U.S. ORTHOPEDIC IMPLANT MARKET BY NUMBER AND TYPE OF PROCEDURE, THROUGH 2013
AUTOGRAFTS
Autografts (Continued)
TABLE 109 U.S. AND WORLD VALUES OF THE BONE GRAFTING MARKET, THROUGH 2013 ($ MILLIONS)
ALLOGRAFTS
Allografts (Continued)
Risks Associated with Allografts
Products
Base Tissue
Demineralized Bone Matrix Products
Machined Implants
THE ORTHOBIOLOGICS MARKET
TABLE 110 GLOBAL ORTHOBIOGICS MARKET, BY PRODUCT, THROUGH 2013 ($ MILLIONS)
The Market for Allografted Tissue
TABLE 111 U.S. SALES OF BONE ALLOGRAFTS BY TYPE, THROUGH 2013 ($ MILLIONS)
FIGURE 8 BONE ALLOGRAFT MARKET, THROUGH 2013 ($ MILLIONS)
BONE GRAFT SUBSTITUTES
TABLE 112 COMPARISON OF BONE GRAFT MATERIALS
TABLE 113 SUBSTITUTE BONE GRAFT
FACTOR-BASED BONE GRAFT SUBSTITUTES
Factor-Based Bone Graft ... (Continued)
Bone Morphogenic Proteins (BMPs)
InductOs
INFUSE Bone Graft
OP-1 Implant
PREVENTING INFECTION
PRESERVATION
COMPETITION
VASCULAR TRANSPLANTATION
HISTORY
INDICATIONS
PROCEDURES
DONORS
HEART VALVES
HEART VALVE ALLOGRAFT MARKET
TABLE 114 U.S. HEART VALVE TRANSPLANT MARKET, THROUGH 2013 ($ MILLIONS)
TISSUE TESTING
SYNTHETICS
XENOGRAFTS
ADVANCES
Symetis
Edwards Life Sciences
BETTER MONITORING
TISSUE VALVES GAIN POPULARITY
MAJOR COMPETITORS
VASCULAR GRAFTS
Indications
Waiting List
Products
ALTERNATIVES TO VASCULAR TRANSPLANTATION
SKIN TRANSPLANTATION
TABLE 115 U.S. MARKET FOR HUMAN SKIN-BASED PRODUCTS, THROUGH 2013
HISTORY
MARKET POTENTIAL
INDICATIONS
Burns
Other Injuries
Cosmetic Surgery
Wounds
Venous Ulcers
TABLE 116 ESTIMATED INCIDENCE OF VENOUS ULCERS IN THE U.S. OVER-64 POPULATION, THROUGH 2013
Diabetic Ulcers
TABLE 117 ESTIMATED U.S. INCIDENCE OF DIABETIC FOOT ULCERS, THROUGH 2013 (MILLIONS)
Pressure Ulcers
Urinary Incontinence and Other Uses
Collagen Meniscus Implant
REJECTION
TISSUE TESTING
PRESERVATION
CELLULAR TRANSPLANTATION
HISTORY
INDICATIONS
TYPES OF CELLS
DONORS
REJECTION
GOVERNMENT REGULATIONS
ALTERNATIVES
CHAPTER 9: ALTERNATIVES TO DONOR TRANSPLANTATION
ALTERNATIVES TO CORNEAL TRANSPLANTATION
SURGICAL
ARTIFICIAL CORNEAS
RETINAL TRANSPLANTS
CELLULAR TRANSPLANTS
ELECTRONIC IMPLANTS
ALTERNATIVES TO INTESTINAL TRANSPLANTATION
MEDICAL
CELLULAR
ALTERNATIVES TO PANCREAS TRANSPLANTATION
MEDICAL
Islet Cell Transplantation
Islet Cell Transplantation (Continued)
Drawbacks
Cell Encapsulation
ReNeuron
Bioartificial Pancreas
Cerco Medical
Cultured Stem Cells
Diminished Need for Transplantation in the Future
COSTS
ALTERNATIVES TO HEART TRANSPLANTATION
MEDICAL
Fibroblast Growth Factors
CardioVascular BioTherapeutic, Inc
Endovasc, Ltd
Gene Therapy
Naked Plasmid DNA Transfer
Adenoviral Vectors
XENOTRANSPLANTATION
SURGICAL
Laser Revascularization
Mitral Valve Repair
CARDIAC SUPPORT DEVICES
Passive Support Systems
MECHANICAL
REGENERATION INSTEAD OF REPLACEMENT
Biophan
MECHANICAL ORGANS
VAD Market
VAD costs
TABLE 118 GLOBAL MARKET FOR VADS, THROUGH 2013 ($ MILLIONS)
TABLE 119 U.S. MARKET FOR VADS USED AS DESTINATION THERAPY, THROUGH 2013 ($ MILLIONS)
DeBakey LVAS
HeartMate
Incor LVAD, Excor VAD
Novacor
VAD DEVELOPMENT IN THE U.S.
TABLE 120 LEFT VENTRICULAR ASSIST DEVICES IN DEVELOPMENT
Arrow International
CardiacAssist
Jarvik
Ventracor
TOTAL ARTIFICIAL HEARTS
AbioMed
CardioWest
OTHER CARDIAC ASSIST DEVICES IN DEVELOPMENT
CELLULAR THERAPY
Bioheart
ALTERNATIVES TO LIVER TRANSPLANTATION
MEDICAL
Vertex Pharmaceuticals
ARTIFICIAL LIVERS
CHEMICAL/MECHANICAL AND/OR BIOARTIFICIAL LIVERS
TABLE 121 INDICATIONS FOR THE BIOARTIFICIAL LIVER
Chemical/Mechanical...(Continued)
TABLE 122 BIOARTIFICIAL LIVERS IN DEVELOPMENT
Bioartificial Liver Support System
ELAD
Modular Extracorporeal Liver Support (MELS)
Molecular Adsorption Recycling System (MARS)
RELATIVE COSTS
ALTERNATIVES TO LUNG TRANSPLANTATION
MEDICAL
SURGICAL
ALTERNATIVES TO BONE GRAFTS
MEDICAL
SYNTHETIC MATERIALS
Orthovita
Spine Wave
ReGen Biologics
ALTERNATIVES TO VASCULAR TRANSPLANTATION
ANIMAL
Stentless Valves
Calcification
SURGICAL
Angioplasty and Stents
MEDICAL
MECHANICAL/SYNTHETIC
ALTERNATIVES TO VASCULAR TRANSPLANTATION
TISSUE ENGINEERING OF VASCULAR GRAFTS
GENE THERAPY
ALTERNATIVES TO SKIN TRANSPLANTATION
ANIMAL-BASED PRODUCTS
Biobrane
OaSIS
GROWTH FACTORS
ARTIFICIAL SKIN/SKIN REPLACEMENT PRODUCTS
AlloDerm
Apligraf
Cymetra
Dermagraft
Epicel
Integra Products
OrCel
TransCyte
MANUFACTURERS OF ARTIFICIAL SKIN AND SKIN REPLACEMENT PRODUCTS
TABLE 123 MANUFACTURERS OF ARTIFICIAL SKIN AND SKIN REPLACMENT PRODUCTS
THE MARKET FOR ARTIFICIAL SKIN AND SKIN REPLACEMENT PRODUCTS
TABLE 124 ESTIMATED WORLDWIDE MARKET FOR ARTIFICIAL SKIN AND SKIN REPLACEMENT PRODUCTS, THROUGH 2013 ($ MILLIONS)
TABLE 125 ESTIMATED U.S. MARKET FOR ARTIFICIAL SKIN AND SKIN REPLACEMENT PRODUCTS, THROUGH 2013 ($ MILLIONS)
PRODUCTS IN DEVELOPMENT
Altex Plus, Ltd.
Cytomedix
Geron
OTHER RESEARCH
REGULATION
CHAPTER 10: COMPANY PROFILES
ABIOMED, INC.
BUSINESS OVERVIEW
FINANCIAL INFORMATION
PRODUCTS
ARBIOS SYSTEMS, INC
BUSINESS OVERVIEW
FINANCIAL INFORMATION
PRODUCTS
ARROW INTERNATIONAL
BUSINESS OVERVIEW
FINANCIAL INFORMATION
PRODUCTS
ASTELLAS PHARMA, INC
BUSINESS OVERVIEW
FINANCIAL INFORMATION
CRYOLIFE, INC.
BUSINESS OVERVIEW
FINANCIAL INFORMATION
PRODUCTS
DEPUY ORTHOPEDICS
BUSINESS OVERVIEW
FINANCIAL INFORMATION
PRODUCTS
EDWARDS LIFESCIENCES
BUSINESS OVERVIEW
FINANCIAL INFORMATION
PRODUCTS
EXACTECH
BUSINESS OVERVIEW
FINANCIAL INFORMATION
PRODUCTS
FORTICELL BIOSCIENCE
BUSINESS OVERVIEW
FINANCIAL INFORMATION
PRODUCTS
FRESENIUS MEDICAL CARE AG & CO. KGAA
BUSINESS OVERVIEW
FINANCIAL INFORMATION
PRODUCTS
GENZYME
BUSINESS OVERVIEW
FINANCIAL INFORMATION
PRODUCTS
HEMOCLEANSE, INC
BUSINESS OVERVIEW
FINANCIAL INFORMATION
PRODUCTS
JOHNSON & JOHNSON
BUSINESS OVERVIEW
FINANCIAL INFORMATION
PRODUCTS
KIADIS PHARMA
BUSINESS OVERVIEW
FINANCIAL INFORMATION
PRODUCTS
KINETIC CONCEPTS, INC (KCI)
BUSINESS OVERVIEW
FINANCIAL INFORMATION
PRODUCTS
LIFEBLOOD MEDICAL, INC
BUSINESS OVERVIEW
FINANCIAL INFORMATION
PRODUCTS
LIFECELL CORP. (SEE KINETIC CONCEPTS, INC)
LIFECYCLE PHARMA A/S
BUSINESS OVERVIEW
FINANCIAL INFORMATION
PRODUCTS
LIVING CELL TECHNOLOGIES, LTD
BUSINESS OVERVIEW
FINANCIAL INFORMATION
PRODUCTS
MEDTRONIC, INC.
BUSINESS OVERVIEW
FINANCIAL INFORMATION
PRODUCTS
NOVARTIS AG
BUSINESS OVERVIEW
FINANCIAL INFORMATION
PRODUCTS
ON-X LIFE TECHNOLGIES, INC
BUSINESS OVERVIEW
FINANCIALS
PRODUCTS
ORGANOGENESIS, INC.
BUSINESS OVERVIEW
FINANCIALS
PRODUCTS
OSTEOTECH
BUSINESS OVERVIEW
FINANCIAL INFORMATION
PRODUCTS
PDL BIOPHARMA
BUSINESS OVERVIEW
FINANCIAL INFORMATION
PRODUCTS
ROCHE PHARMACEUTICALS
BUSINESS OVERVIEW
FINANCIALS
PRODUCTS
SORIN GROUP, S.P.A
BUSINESS OVERVIEW
FINANCIALS
PRODUCTS
ST. JUDE MEDICAL
BUSINESS OVERVIEW
FINANCIALS
PRODUCTS
STRYKER CORPORATION
BUSINESS OVERVIEW
FINANCIAL INFORMATION
PRODUCTS
SYNCARDIA SYSTEMS, INC
BUSINESS OVERVIEW
FINANCIALS
PRODUCTS
SYTHES (US)
BUSINESS OVERVIEW
FINANCIAL INFORMATION
PRODUCTS
TRANSMEDICS, INC
BUSINESS OVERVIEW
FINANCIALS
PRODUCTS
THORATEC CORP.
BUSINESS OVERVIEW
FINANCIAL INFORMATION
PRODUCTS
VENTRACOR
BUSINESS OVERVIEW
FINANCIAL INFORMATION
PRODUCTS
VIROPHARMA, INC
BUSINESS OVERVIEW
FINANCIAL INFORMATION
PRODUCTS
WORLD HEART CORP
BUSINESS OVERVIEW
FINANCIAL INFORMATION
PRODUCTS
WYETH
BUSINESS OVERVIEW
FINANCIAL INFORMATION
PRODUCTS
LIST OF TABLES
SUMMARY TABLE U.S. MARKET FOR SOLID ORGAN AND TISSUE TRANSPLANTATION, THROUGH 2013 ($ MILLIONS)
TABLE 1 U.S. ORGAN TRANSPLANTS: AVERAGE FIRST YEAR COST, NUMBER OF PROCEDURES AND VALUE BY TYPE OF ORGAN TRANSPLANT, THROUGH 2013 ($ MILLIONS)
TABLE 2 LEADING U.S. KIDNEY TRANSPLANT PROGRAMS BY TOTAL NUMBER OF PROCEDURES PERFORMED IN 2007
TABLE 3 TOP FIVE U.S. LIVER TRANSPLANT PROGRAMS BY TOTAL PROCEDURES PERFORMED IN 2007
TABLE 4 TOP FIVE U.S. HEART TRANSPLANT PROGRAMS BY TOTAL PROCEDURES PERFORMED IN 2007
TABLE 5 TOP FIVE U.S. LUNG TRANSPLANT PROGRAMS BY TOTAL PROCEDURES PERFORMED IN 2007
TABLE 6 TOP FIVE U.S. INTESTINE/SMALL BOWEL TRANSPLANT PROGRAMS BY TOTAL PROCEDURES PERFORMED IN 2007
TABLE 7 TOP FIVE U.S. PANCREAS TRANSPLANT PROGRAMS BY TOTAL PROCEDURES PERFORMED IN 2007
TABLE 8 TISSUE GRAFTING IN THE U.S. BY TISSUE TYPE, THROUGH 2013 (MILLION PROCEDURES)
TABLE 9 PATIENTS ON U.S. WAITING LISTS AT THE END OF THE YEAR BY TYPE OF ORGAN TRANSPLANT, 2003-2006
TABLE 10 TRENDS IN U.S. LIVING AND CADAVERIC DONATIONS, THROUGH 2013
TABLE 11 U.S. ORGAN TRANSPLANTS, THROUGH 2006 (NUMBER OF PROCEDURES)
TABLE 12 NUMBERS OF DONATED CADAVERS BY REGION, 2003-2006
TABLE 13 ONE-YEAR AND FIVE-YEAR PATIENT SURVIVAL RATES, BY ORGAN FOR TRANSPLANTS PERFORMED, 1997-2004 (%)
TABLE 14 ONE-YEAR AND FIVE-YEAR GRAFT SURVIVAL RATES, BY ORGAN FOR TRANSPLANTS PERFORMED, 1997-2004 (%)
TABLE 15 NUMBER OF PEOPLE IN THE U.S. LIVING WITH A FUNCTIONING TRANSPLANT BY TYPE, 2000-2005*
TABLE 16 IMMUNOSUPPRESSIVE DRUGS CURRENTLY COVERED BY MEDICARE*
TABLE 17 MEDICARE IMMUNOSUPPRESIVE DRUG COVERAGE OVERVIEW
TABLE 18 WORLD MARKET FOR HLA TYPING, THROUGH 2013 ($ MILLIONS)
TABLE 19 U.S. MARKET FOR HLA TYPING, THROUGH 2013 ($ MILLIONS)
TABLE 20 PRESERVATION TIME FOR TRANSPLANTED ORGANS (HOURS)
TABLE 21 IMMUNOSUPPRESSIVE DRUGS APPROVED IN THE U.S. BY CLASS
TABLE 22 ANTIBODY PRODUCTS FOR TREATMENT OF ORGAN TRANSPLANT REJECTION
TABLE 23 COMMONLY USED INTRAVENOUS ANTIBODY IMMUNOSUPPRESIVE DRUGS
TABLE 24 GLOBAL MARKET FOR ANTIBODY PRODUCTS TO TREAT ORGAN TRANSPLANT REJECTION, THROUGH 2013 ($ MILLIONS)
TABLE 25 GLOBAL MARKET FOR ANTIPROLIFERATIVE AGENTS TO TREAT ORGAN TRANSPLANT REJECTION: WORLDWIDE SALES, THROUGH 2013 ($ MILLIONS)
TABLE 26 GLOBAL MARKET FOR CALCINEURIN INHIBITORS TO TREAT ORGAN TRANSPLANT REJECTION: WORLDWIDE SALES, THROUGH 2013 ($ MILLIONS)
TABLE 27 GLOBAL MARKET FOR M-TOR INHIBITORS TO TREAT ORGAN TRANSPLANT REJECTION: WORLDWIDE SALES, THROUGH 2013 ($ MILLIONS)
TABLE 28 U.S. SALES OF IMMUNOSUPPRESSIVES BY DRUG CATEGORY, THROUGH 2013 ($ MILLIONS)
TABLE 29 SELECTED IMMUNOSUPPRESSIVE AGENTS IN PHASE 1 OR LATER DEVELOPMENT
TABLE 30 COMMON IMMUNOSUPPRESSIVE REGIMENS
TABLE 31 IMMUNOSUPPRESSANT USE FOR INDUCTION, BY ORGAN IN 2006 (%)
TABLE 32 IMMUNOSUPPRESSANT USE FOR MAINTENANCE AT DISCHARGE BY ORGAN IN THE U.S., 2006 (%)
TABLE 33 IMMUNOSUPPRESSANT USE FOR MAINTENANCE AT 1-YEAR POST-TRANSPLANT BY ORGAN IN U.S., 2006 (%)
TABLE 34 WORLDWIDE MARKET FOR IMMUNOSUPPRESSION IN SOLID ORGAN TRANSPLANT RECIPIENTS, THROUGH 2013
TABLE 35 GLOBAL SALES OF IMMUNOSUPPRESSIVES BY DRUG CATEGORY, THROUGH 2013 ($ MILLIONS)
TABLE 36 WORLDWIDE SALES OF BRAND NAME IMMUNOSUPPRESSANT DRUGS BY COMPANY, 2006 AND 2007 ($ MILLIONS)
TABLE 37 COMMON POST-TRANSPLANT INFECTIONS
TABLE 38 TIMELINE FOR POST-TRANSPLANT INFECTION
TABLE 39 COMMON POST-TRANSPLANT DRUGS
TABLE 40 WORLD MARKET FOR ANTI-INFECTIVES USED FOR TRANSPLANT PATIENTS, THROUGH 2013 ($ MILLIONS)
TABLE 41 U.S. MARKET FOR POST-TRANSPLANT MONITORING, THROUGH 2013 ($ MILLIONS)
TABLE 42 RECOVERED ORGANS NOT USED BY TYPE, 2003-2006
TABLE 43 CONSENTED ORGANS NOT RECOVERED BY TYPE, 2003-2006
TABLE 44 MAJOR ORGAN PRESERVATION SOLUTIONS
TABLE 45 NORTH AMERICAN AND WORLD MARKETS FOR ORGAN PRESERVATION SOLUTIONS (NOT INCLUDING THE PAPWORK COCKTAIL), THROUGH 2013 ($ MILLIONS)
TABLE 46 U.S. ORGAN RECIPIENTS WHO PREVIOUSLY HAD A TRANSPLANT: ALL ORGANS, 2003-2006
TABLE 47 LEADING U.S. TRANSPLANT PROGRAMS BY TOTAL NUMBER OF PROCEDURES PERFORMED IN 2007
TABLE 48 TISSUE TYPING TECHNOLOGIES
TABLE 49 SELECTED COMPETITORS IN THE HLA TYPING MARKET
TABLE 50 U.S. MARKET FOR KIDNEY-ONLY TRANSPLANTATION, THROUGH 2013
TABLE 51 ESTIMATED U.S. MARKET FOR IMMUNOSUPPRESSIVES FOR KIDNEY TRANSPLANT PATIENTS, THROUGH 2013 ($ MILLION)
TABLE 52 U.S. IMMUNOSUPPRESSION DRUG USE FOR INDUCTION IN KIDNEY TRANSPLANTATION, 2003-2006 (%)
TABLE 53 U.S. IMMUNOSUPPRESSION DRUG USE FOR MAINTENANCE BEFORE DISCHARGE AFTER KIDNEY TRANSPLANTATION, 2003-2006 (%)
TABLE 54 IMMUNOSUPPRESSION DRUG USE IN THE U.S. FOR MAINTENANCE BETWEEN DISCHARGE AND ONE-YEAR POSTTRANSPLANT FOR KIDNEY TRANSPLANTATION, 2002-2005 (%)
TABLE 55 U.S. MARKET FOR PANCREAS TRANSPLANTATION, THROUGH 2013
TABLE 56 U.S. PANCREAS WAITING LIST, THROUGH 2013
TABLE 57 ESTIMATED U.S. MARKET FOR IMMUNOSUPPRESSIVES FOR PANCREAS TRANSPLANT PATIENTS, THROUGH 2013
TABLE 58 U.S. IMMUNOSUPPRESSION DRUG USE FOR INDUCTION IN PANCREAS TRANSPLANTATION, 2003-2006 (%)
TABLE 59 U.S. IMMUNOSUPPRESSION DRUG USE FOR MAINTENANCE BEFORE DISCHARGE AFTER PANCREAS TRANSPLANTATION, 2003-2006 (%)
TABLE 60 IMMUNOSUPPRESSION DRUG USE IN THE U.S. FOR MAINTENANCE BETWEEN DISCHARGE AND 1-YEAR POSTTRANSPLANT FOR PANCREAS TRANSPLANTATION, 2002-2005 (%)
TABLE 61 U.S. HEART TRANSPLANT MARKET, THROUGH 2013 ($ MILLIONS)
TABLE 62 ESTIMATED U.S. MARKET FOR IMMUNOSUPPRESSIVES FOR HEART TRANSPLANT PATIENTS, THROUGH 2013
TABLE 63 U.S. IMMUNOSUPPRESSION DRUG USE FOR INDUCTION IN HEART TRANSPLANTATION, 2003-2006 (%)
TABLE 64 U.S. IMMUNOSUPPRESSION DRUG USE FOR MAINTENANCE PRIOR TO DISCHARGE IN HEART TRANSPLANTATION, 2003-2006 (%)
TABLE 65 U.S. IMMUNOSUPPRESSION DRUG USE FOR ANTIREJECTION BETWEEN DISCHARGE AND 1-YEAR POSTTRANSPLANT IN HEART TRANSPLANTATION, 2002-2005
TABLE 66 LEADING CAUSES OF HEART FAILURE, 2002-2006 (%)
TABLE 67 U.S. LIVER TRANSPLANT MARKET, FIRST YEAR, THROUGH 2013 ($ MILLIONS)
TABLE 68 REGIONAL GROWTH IN LIVER WAITING LISTS, THROUGH 2013
TABLE 69 U.S. IMMUNOSUPPRESSION DRUG USE FOR INDUCTION IN LIVER TRANSPLANTATION, 2003-2006 (%)
TABLE 70 U.S. IMMUNOSUPPRESSION DRUG USE FOR MAINTENANCE PRIOR TO DISCHARGE IN LIVER TRANSPLANTATION, 2003-2006 (%)
TABLE 71 U.S. IMMUNOSUPPRESSION DRUG USE FOR MAINTENANCE BETWEEN DISCHARGE AND 1-YEAR POSTTRANSPLANT FOR LIVER TRANSPLANTATION, 2002-2005 (%)
TABLE 72 U.S. IMMUNOSUPPRESSION DRUG USE FOR ANTIREJECTION BETWEEN TRANSPLANT AND 1-YEAR POSTTRANSPLANT FOR LIVER TRANSPLANTATION, 2002-2005 (%)
TABLE 73 ESTIMATED U.S. MARKET FOR IMMUNOSUPPRESSIVES FOR LIVER TRANSPLANT PATIENTS, THROUGH 2013 ($ MILLIONS)
TABLE 74 LIVER TRANSPLANT SURVIVAL RATES IN THE U.S. AND EUROPE, 2003 (%)
TABLE 75 U.S. LUNG TRANSPLANTATION MARKET, THROUGH 2013 ($ MILLIONS)
TABLE 76 LEADING CAUSES OF CHRONIC LUNG FAILURE IN THE U.S., 2002-2006 (%)
TABLE 77 ESTIMATED U.S. MARKET FOR IMMUNOSUPPRESSIVES FOR LUNG TRANSPLANT PATIENTS, THROUGH 2013 ($ MILLIONS)
TABLE 78 U.S. IMMUNOSUPPRESSION DRUG USE FOR INDUCTION IN LUNG TRANSPLANTATION, 2003-2006 (%)
TABLE 79 U.S. IMMUNOSUPPRESSION DRUG USE FOR MAINTENANCE PRIOR TO DISCHARGE IN LUNG TRANSPLANTATION, 2002-2006 (%)
TABLE 80 U.S. IMMUNOSUPPRESSION DRUG USE FOR MAINTENANCE BETWEEN DISCHARGE AND 1-YEAR POSTTRANSPLANT IN LUNG TRANSPLANTATION, 2003-2006 (%)
TABLE 81 U.S. IMMUNOSUPPRESSION DRUG USE FOR ANTIREJECTION BETWEEN TRANSPLANT AND 1-YEAR POSTTRANSPLANT IN LUNG TRANSPLANTATION, 2002-2005 (%)
TABLE 82 U.S. LUNG TRANSPLANT PATIENT AND GRAFT SURVIVAL RATES* (%)
TABLE 83 U.S. HEART-LUNG TRANSPLANT MARKET, THROUGH 2013 ($ MILLIONS)
TABLE 84 ESTIMATED U.S. MARKET FOR IMMUNOSUPPRESSIVES FOR HEART-LUNG TRANSPLANT PATIENTS, THROUGH 2013 ($ MILLIONS)
TABLE 85 U.S. IMMUNOSUPPRESSION DRUG USE FOR INDUCTION IN HEART-LUNG TRANSPLANTATION, 2003-2006 (%)
TABLE 86 U.S. IMMUNOSUPPRESSION DRUG USE FOR MAINTENANCE PRIOR TO DISCHARGE IN HEART-LUNG TRANSPLANTATION, 2003-2006 (%)
TABLE 87 U.S. IMMUNOSUPPRESSION DRUG USE FOR MAINTENANCE BETWEEN DISCHARGE AND 1-YEAR POSTTRANSPLANT IN HEART-LUNG TRANSPLANTATION, 2002-2005 (%)
TABLE 88 U.S. IMMUNOSUPPRESSION DRUG USE FOR ANTIREJECTION BETWEEN TRANSPLANT AND 1-YEAR POSTTRANSPLANT IN HEART-LUNG TRANSPLANTATION, 2002-2005 (%)
TABLE 89 U.S. HEART-LUNG WAITING LIST TRENDS, THROUGH 2013
TABLE 90 U.S. HEART-LUNG TRANSPLANT PATIENT AND GRAFT SURVIVAL RATES (%)
TABLE 91 LEADING INDICATIONS FOR INTESTINE TRANSPLANT: ADULT PATIENTS
TABLE 92 LEADING INDICATIONS FOR INTESTINE TRANSPLANT: PEDIATRIC PATIENTS
TABLE 93 U.S. SMALL BOWEL TRANSPLANTATION TRENDS, THROUGH 2013
TABLE 94 U.S. SMALL BOWEL TRANSPLANTATION MARKET, THROUGH 2013 ($ MILLIONS)
TABLE 95 COUNTRIES WITH SMALL BOWEL TRANSPLANT PROGRAMS
TABLE 96 ESTIMATED U.S. MARKET FOR IMMUNOSUPPRESSIVES FOR HEART-LUNG TRANSPLANT PATIENTS, THROUGH 2013 ($ MILLIONS)
TABLE 97 U.S. IMMUNOSUPPRESSION DRUG USE FOR INDUCTION IN INTESTINE TRANSPLANTATION, 2003-2006 (%)
TABLE 98 U.S. IMMUNOSUPPRESSION DRUG USE FOR MAINTENANCE PRIOR TO DISCHARGE IN INTESTINE TRANSPLANTATION, 2003-2006 (%)
TABLE 99 U.S. IMMUNOSUPPRESSION DRUG USE FOR MAINTENANCE BETWEEN DISCHARGE AND 1-YEAR POSTTRANSPLANT IN INTESTINE TRANSPLANTATION, 2002-2005 (%)
TABLE 100 U.S. IMMUNOSUPPRESSION DRUG USE FOR ANTIREJECTION BETWEEN TRANSPLANT AND 1-YEAR POSTTRANSPLANT IN INTESTINE TRANSPLANTATION, 2002-2005 (%)
TABLE 101 U.S. CORNEAL TRANSPLANT MARKET, THROUGH 2013
TABLE 102 PROJECTED U.S. HEMATOPOIETIC STEM CELL TRANSPLANT PROCEDURES, THROUGH 2013
TABLE 103 BMDW MEMBER HOME COUNTRIES
TABLE 104 NUMBER OF BONE MARROW DONORS, BY COUNTRY
TABLE 105 U.S. MARKET FOR IMMUNOSUPPRESSIVE DRUG THERAPY FOLLOWING HEMATOPOIETIC TRANSPLANTATION, THROUGH 2013 ($ MILLIONS)
TABLE 106 U.S. BONE GRAFT PROCEDURE VOLUMES BY TYPE OF GRAFT, THROUGH 2013
TABLE 107 U.S. AND WORLDWIDE ORTHOPEDIC IMPLANT MARKET GROWTH, THROUGH 2013 ($ MILLIONS)
TABLE 108 U.S. ORTHOPEDIC IMPLANT MARKET BY NUMBER AND TYPE OF PROCEDURE, THROUGH 2013
TABLE 109 U.S. AND WORLD VALUES OF THE BONE GRAFTING MARKET, THROUGH 2013 ($ MILLIONS)
TABLE 110 GLOBAL ORTHOBIOGICS MARKET, BY PRODUCT, THROUGH 2013 ($ MILLIONS)
TABLE 111 U.S. SALES OF BONE ALLOGRAFTS BY TYPE, THROUGH 2013 ($ MILLIONS)
TABLE 112 COMPARISON OF BONE GRAFT MATERIALS
TABLE 113 SUBSTITUTE BONE GRAFT
TABLE 114 U.S. HEART VALVE TRANSPLANT MARKET, THROUGH 2013 ($ MILLIONS)
TABLE 115 U.S. MARKET FOR HUMAN SKIN-BASED PRODUCTS, THROUGH 2013
TABLE 116 ESTIMATED INCIDENCE OF VENOUS ULCERS IN THE U.S. OVER-64 POPULATION, THROUGH 2013
TABLE 117 ESTIMATED U.S. INCIDENCE OF DIABETIC FOOT ULCERS, THROUGH 2013 (MILLIONS)
TABLE 118 GLOBAL MARKET FOR VADS, THROUGH 2013 ($ MILLIONS)
TABLE 119 U.S. MARKET FOR VADS USED AS DESTINATION THERAPY, THROUGH 2013 ($ MILLIONS)
TABLE 120 LEFT VENTRICULAR ASSIST DEVICES IN DEVELOPMENT
TABLE 121 INDICATIONS FOR THE BIOARTIFICIAL LIVER
TABLE 122 BIOARTIFICIAL LIVERS IN DEVELOPMENT
TABLE 123 MANUFACTURERS OF ARTIFICIAL SKIN AND SKIN REPLACMENT PRODUCTS
TABLE 124 ESTIMATED WORLDWIDE MARKET FOR ARTIFICIAL SKIN AND SKIN REPLACEMENT PRODUCTS, THROUGH 2013 ($
MILLIONS)
TABLE 125 ESTIMATED U.S. MARKET FOR ARTIFICIAL SKIN AND SKIN REPLACEMENT PRODUCTS, THROUGH 2013 ($ MILLIONS)
LIST OF FIGURES
SUMMARY FIGURE U.S. MARKET FOR SOLID ORGAN AND TISSUE TRANSPLANTATION, 2007-2013 ($ MILLIONS)
FIGURE 1 U.S. MARKET FOR TISSUE GRAFTING PROCEDURES BY TYPE, 2007-2013 (MILLION PROCEDURES)
FIGURE 2 GLOBAL MARKET FOR ANTIBODY PRODUCTS USED IN ORGAN TRANSPLANTATION, 2007-2013 ($ MILLIONS)
FIGURE 3 GLOBAL MARKET FOR ANTIPROLIFERATIVE AGENTS, 2007-2013 ($ MILLIONS)
FIGURE 4 GLOBAL MARKET FOR CALCINEURIN INHIBITORS, 2007-2013 ($ MILLIONS)
FIGURE 5 U.S. SALES OF IMMUNOSUPPRESSIVES, BY CATEGORY, THROUGH 2013 ($ MILLIONS)
FIGURE 6 WORLDWIDE SALES OF IMMUNOSUPPRESSANTS BY CATEGORY, 2007-2013 ($ MILLIONS)
FIGURE 7 U.S. BONE GRAFT PROCEDURES, 2007-2013 ($ MILLIONS)
FIGURE 8 BONE ALLOGRAFT MARKET, THROUGH 2013 ($ MILLIONS)
To order this report:
Organ and Tissue Transplantation and Alternatives
www.reportlinker.com/p096592/Organ-and-Tissue- Transplantation-and-Alternatives.html
(Due to its length, this URL may need to be copied/pasted into your Internet browser's address field. Remove the extra space if one exists.)
More market research reports here!
Reportlinker
Nicolas: nbo@reportlinker.com
US: (805)-652-2626
Intl: +1 805-652-2626
